Drugs / Alpha-tocopheryloxyacetic Acid
Alpha-tocopheryloxyacetic Acid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04120246 | Apr 2020 → Feb 2028 | HER2 positive breast carcinoma, female breast carcinoma | Veana Therapeutics | Suspended | No outcome recorded |
| Phase 1 | NCT02192346 | Aug 2014 → Dec 2017 | lymphoma, metastatic carcinoma, sarcoma | Providence Health & Services | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-tocopheryloxyacetic Acid | “Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer” NCT02192346 ↗ |
| Known as | .alpha.-tea | ChEMBL registry synonym — accepted as the source's own label CHEMBL2152999 ↗ |
| Known as | α-TEA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02192346 ↗ |
| Modality | Small molecule | — CHEMBL2152999 ↗ |
| Route | Oral | “Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.” NCT02192346 ↗ |